Clinical Trials Search Results

  • Resize font
  • Print
  • Email
  • Facebook
  • Twitter
  • Google+
  • Pinterest

Initial search results include only NCI-sponsored clinical trials. To search all trials, click the "REFINE SEARCH" button, scroll down to the Trial ID/Sponsor section and select the "All" check box in the Sponsor of Trial section.

View Content for:
Display:
?
Drug:  Hsp90 inhibitor SNX-5422 mesylate
Find trials that include:  Any drugs shown
Trial Status:  Closed
Results 1-5 of 5 for your search:
Start Over
Safety And Pharmacology Study Of SNX-5422 Mesylate In Subjects With Refractory Solid Tumor Malignancies
Phase: Phase I
Type: Treatment
Status: Completed
Age: Over 18
Sponsor: Pharmaceutical / Industry
Protocol IDs: B1311001, SNX-5422-CLN1-001, NCT00506805
Safety And Pharmacology Of SNX-5422 Mesylate In Subjects With Refractory Hematological Malignancies
Phase: Phase I
Type: Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: B1311002, SNX-5422-CLN1-002, NCT00595686
Phase I Study of Hsp90 Inhibitor SNX-5422 Mesylate in Patients With Refractory Solid Tumors or Lymphomas
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Closed
Age: 18 and over
Sponsor: NCI
Protocol IDs: NCI-08-C-0091, 08-C-0091, NCI-P07318, NCT00644072
Safety and Pharmacology Study of SNX-5422 in Subjects With Refractory Solid Tumor Malignancies
Phase: Phase I
Type: Biomarker/Laboratory analysis, Treatment
Status: Completed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SNX-5422-CLN1-004, NCT01611623
Safety and Pharmacology Study of SNX-5422 in Subjects With Resistant Lung Adenocarcinoma
Phase: Phase I
Type: Supportive care, Treatment
Status: Closed
Age: 18 and over
Sponsor: Pharmaceutical / Industry
Protocol IDs: SNX-5422-CLN1-007, NCT01851096
Start Over